Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib and Avelumab with Hypofractionated Radiation in Advanced Solid Tumors and Hepatobiliary Malignancies
NCT04068194Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2020
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of peposertib in solid tumor, cholangiocarcinoma (CCA), gallbladder carcinoma, sponsored by National Cancer Institute. Started Apr 2020; status: active, not recruiting.
02
Drugs
peposertib
03
Conditions
solid tumorcholangiocarcinoma (CCA)gallbladder carcinoma
Beyond the preview
Go deeper on NCT04068194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068194.